Aprea Therapeutics (APRE)_個股概要_股票價格_行情走勢圖

5.450
+0.200+3.81%

收盤價 05/02 16:00 (美東)

2959.47萬總市值-1379市盈率TTM

代碼股票名稱

最新價漲跌額漲跌幅成交量成交額今開昨收最高最低總市值流通市值總股本流通股本5日漲跌幅10日漲跌幅20日漲跌幅60日漲跌幅120日漲跌幅250日漲跌幅年初至今漲跌幅股息率TTM換手率市盈率TTM市盈率(靜)振幅所屬行業

評論

Jaguar8

04/11 00:11

$Aprea Therapeutics(APRE.US)$
NEWS
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
Aprea Therapeutics, Inc. announces positive pre-clinical findings for APR-1051, a WEE1 kinase inhibitor, indicating potential as a treatment for Cyclin E-overexpressing cancers. The company also received IND clearance for APR-1051 and presented details on the planned Phase 1 trial. ATRN-119, a n...

Trytosaveabit

03/14 19:52

Update

$Aprea Therapeutics(APRE.US)$ Karolinska Development's Portfolio Company Aprea Therapeutics Receives FDA IND Approval and Secures Funding of USD 34 Million
GlobeNewswire· 4 mins ago

Stock Region

03/12 08:12

$34M Private Placement & FDA Clearance Secured By Therapeutics Company For Novel Cancer Treatment

Aprea Therapeutics Secures $34M in Private Placement Financing: A Major Step Forward in Oncology Research.
In a significant development in the field of precision oncology, Aprea Therapeutics, Inc. (NASDAQ: APRE) announced a private placement financing of up to $34 million. The financing is set to close around March 13, 2024, subject to customary closing conditions. The proceeds will be used to fund a...